Solid State Forms Of Mavacamten And Process For Preparation Thereof

Patent No. EP4097091 (titled "Solid State Forms Of Mavacamten And Process For Preparation Thereof") was filed by Assia Chemical Industries on Jan 28, 2021. The application was issued on Sep 18, 2024.

Patent Summary

Solid-state forms of Mavacamten, including crystalline polymorphs, for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), comprising anhydrous crystalline polymorphs of Mavacamten that exhibit stable crystal structures under various conditions. These crystalline polymorphs, including Form 1 and Form 5, have distinct crystal structures and physical properties like melting point, thermal behaviors, X-ray diffraction patterns, infrared absorption fingerprint, and solid-state (13C) NMR spectra, which enable formulation optimization for pharmaceutical applications.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP4097091

ASSIA CHEMICAL INDUSTRIES
Application Number
EP21706793A
Filing Date
Jan 28, 2021
Status
Granted And Under Opposition
Aug 15, 2024
Publication Date
Sep 18, 2024